Skip to main content
Erschienen in: Journal of Neurology 10/2014

01.10.2014 | Original Communication

An electrophysiological classification associated with Guillain–Barré syndrome outcomes

verfasst von: Takafumi Hosokawa, Hideto Nakajima, Kiichi Unoda, Kazushi Yamane, Yoshimitsu Doi, Shimon Ishida, Fumiharu Kimura, Toshiaki Hanafusa

Erschienen in: Journal of Neurology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Guillain–Barré syndrome (GBS) is an acute, post-infectious, inflammatory, autoimmune peripheral neuropathy with a highly diverse clinical course and outcome. We classified GBS on the basis of patients’ first nerve conduction and validated this system to be associated with outcome on the basis of electrophysiological characteristics during the acute phase of GBS. We retrospectively evaluated 40 GBS patients who underwent their first electrophysiological study within 14 days of onset and classified GBS into four patterns: (1) acute inflammatory demyelinating polyneuropathy (AIDP) pattern with sensory nerve conduction abnormalities (motor–sensory AIDP: MS-AIDP), (2) AIDP pattern without sensory nerve conduction abnormalities (motor AIDP: M-AIDP), (3) acute motor axonal neuropathy (AMAN) pattern, and (4) minor abnormalities pattern. We compared the clinical, electrophysiological, and laboratory findings between groups and determined subgroups associated with poor outcome. The MS-AIDP and AMAN patterns more frequently exhibited prolonged recovery compared with the M-AIDP and minor abnormalities patterns and were associated with prolonged recovery (specificity, 100 %; sensitivity, 73 %; P < 0.001). The period of inability to walk independently was significantly longer in the MS-AIDP and AMAN patterns than in the M-AIDP and minor abnormalities patterns (median 85 vs. 10 days; P < 0.001). In conclusion, our classification of GBS using a single nerve conduction study in the early phase of disease is associated with outcomes. This classification can be used to counsel individual patients and guide decision-making with respect to treatment.
Literatur
1.
Zurück zum Zitat Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (1995) Guillain–Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118(Pt 3):597–605CrossRefPubMed Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (1995) Guillain–Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118(Pt 3):597–605CrossRefPubMed
2.
Zurück zum Zitat Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW (1986) An acute axonal form of Guillain–Barré polyneuropathy. Brain 109(Pt 6):1115–1126CrossRefPubMed Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW (1986) An acute axonal form of Guillain–Barré polyneuropathy. Brain 109(Pt 6):1115–1126CrossRefPubMed
3.
Zurück zum Zitat McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP et al (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33:333–342CrossRefPubMed McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP et al (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33:333–342CrossRefPubMed
5.
Zurück zum Zitat Kuwabara S, Yuki N (2013) Axonal Guillain–Barré syndrome: concepts and controversies. Lancet Neurol 12:1180–1188CrossRefPubMed Kuwabara S, Yuki N (2013) Axonal Guillain–Barré syndrome: concepts and controversies. Lancet Neurol 12:1180–1188CrossRefPubMed
6.
Zurück zum Zitat Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M (1998) IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain–Barré syndrome. Ann Neurol 44:202–208CrossRefPubMed Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M (1998) IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain–Barré syndrome. Ann Neurol 44:202–208CrossRefPubMed
7.
Zurück zum Zitat Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A (2003) Acute motor conduction block neuropathy Another Guillain–Barré syndrome variant. Neurology 61:617–622CrossRefPubMed Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A (2003) Acute motor conduction block neuropathy Another Guillain–Barré syndrome variant. Neurology 61:617–622CrossRefPubMed
8.
Zurück zum Zitat Hiraga A, Kuwabara S, Ogawara K, Misawa S, Kanesaka T, Koga M, Yuki N, Hattori T, Mori M (2005) Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barré syndrome. Neurology 64:856–860CrossRefPubMed Hiraga A, Kuwabara S, Ogawara K, Misawa S, Kanesaka T, Koga M, Yuki N, Hattori T, Mori M (2005) Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barré syndrome. Neurology 64:856–860CrossRefPubMed
9.
Zurück zum Zitat Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N (2010) Conduction block in acute motor axonal neuropathy. Brain 133:2897–2908CrossRefPubMed Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N (2010) Conduction block in acute motor axonal neuropathy. Brain 133:2897–2908CrossRefPubMed
10.
Zurück zum Zitat Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T (1998) Two patterns of clinical recovery in Guillain–Barré syndrome with IgG anti-GM1 antibody. Neurology 51:1656–1660CrossRefPubMed Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T (1998) Two patterns of clinical recovery in Guillain–Barré syndrome with IgG anti-GM1 antibody. Neurology 51:1656–1660CrossRefPubMed
11.
Zurück zum Zitat Uncini A, Manzoli C, Notturno F, Capasso M (2010) Pitfalls in electrodiagnosis of Guillain–Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 81:1157–1163CrossRefPubMed Uncini A, Manzoli C, Notturno F, Capasso M (2010) Pitfalls in electrodiagnosis of Guillain–Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 81:1157–1163CrossRefPubMed
12.
Zurück zum Zitat Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A, Kanesaka T, Hattori T, Yuki N (2004) Does Campylobacter jejuni infection elicit “demyelinating” Guillain–Barré syndrome? Neurology 63:529–533CrossRefPubMed Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A, Kanesaka T, Hattori T, Yuki N (2004) Does Campylobacter jejuni infection elicit “demyelinating” Guillain–Barré syndrome? Neurology 63:529–533CrossRefPubMed
13.
Zurück zum Zitat Kuwabara S, Ogawara K, Misawa S, Mizobuchi K, Sung JY, Kitano Y, Mori M, Hattori T (2004) Sensory nerve conduction in demyelinating and axonal Guillain–Barré syndromes. Eur Neurol 51:196–198CrossRefPubMed Kuwabara S, Ogawara K, Misawa S, Mizobuchi K, Sung JY, Kitano Y, Mori M, Hattori T (2004) Sensory nerve conduction in demyelinating and axonal Guillain–Barré syndromes. Eur Neurol 51:196–198CrossRefPubMed
14.
Zurück zum Zitat Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, Kanai K, Noto Y, Fujimaki Y, Shibuya K, Ohmori S, Sato Y, Kuwabara S (2012) Antiganglioside antibodies are associated with axonal Guillain–Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 83:23–28CrossRefPubMed Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, Kanai K, Noto Y, Fujimaki Y, Shibuya K, Ohmori S, Sato Y, Kuwabara S (2012) Antiganglioside antibodies are associated with axonal Guillain–Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 83:23–28CrossRefPubMed
15.
Zurück zum Zitat The Italian Guillain-Barré Study Group (1996) The prognosis and main prognostic indicators of Guillain–Barré syndrome. A multicentre prospective study of 297 patients. Brain 119 (Pt 6):2053–2061 The Italian Guillain-Barré Study Group (1996) The prognosis and main prognostic indicators of Guillain–Barré syndrome. A multicentre prospective study of 297 patients. Brain 119 (Pt 6):2053–2061
16.
Zurück zum Zitat The Emilia-Romagna Study group on Clinical and Epidemiological Problems in Neurology (1997) A prospective study on the incidence and prognosis of Guillain–Barré syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology 48:214–221 The Emilia-Romagna Study group on Clinical and Epidemiological Problems in Neurology (1997) A prospective study on the incidence and prognosis of Guillain–Barré syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology 48:214–221
17.
Zurück zum Zitat Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R (2003) Guillain–Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150CrossRefPubMed Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R (2003) Guillain–Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150CrossRefPubMed
18.
Zurück zum Zitat McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA (1988) Plasmapheresis and Guillain–Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23:347–353CrossRefPubMed McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA (1988) Plasmapheresis and Guillain–Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23:347–353CrossRefPubMed
19.
Zurück zum Zitat Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meche FG (1999) Prognostic factors of Guillain–Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain–Barré Study Group. Neurology 53:598–604CrossRefPubMed Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meche FG (1999) Prognostic factors of Guillain–Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain–Barré Study Group. Neurology 53:598–604CrossRefPubMed
20.
Zurück zum Zitat Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol 27(Suppl):S21–S24CrossRefPubMed Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol 27(Suppl):S21–S24CrossRefPubMed
21.
Zurück zum Zitat Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, Hirata K, Notturno F, Uncini A (2012) Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 259:1181–1190CrossRefPubMed Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, Hirata K, Notturno F, Uncini A (2012) Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 259:1181–1190CrossRefPubMed
22.
Zurück zum Zitat Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750–753CrossRefPubMed Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750–753CrossRefPubMed
23.
Zurück zum Zitat Kimura J (1989) electrodiagnosis in diseases of nerve and muscle: principles and practice. F.A Davis, Philadelphia Kimura J (1989) electrodiagnosis in diseases of nerve and muscle: principles and practice. F.A Davis, Philadelphia
24.
Zurück zum Zitat Isose S, Kuwabara S, Kokubun N, Sato Y, Mori M, Shibuya K, Sekiguchi Y, Nasu S, Fujimaki Y, Noto Y, Sawai S, Kanai K, Hirata K, Misawa S (2009) Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 14:151–158CrossRefPubMed Isose S, Kuwabara S, Kokubun N, Sato Y, Mori M, Shibuya K, Sekiguchi Y, Nasu S, Fujimaki Y, Noto Y, Sawai S, Kanai K, Hirata K, Misawa S (2009) Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 14:151–158CrossRefPubMed
25.
Zurück zum Zitat Kalita J, Misra UK, Das M (2008) Neurophysiological criteria in the diagnosis of different clinical types of Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry 79:289–293CrossRefPubMed Kalita J, Misra UK, Das M (2008) Neurophysiological criteria in the diagnosis of different clinical types of Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry 79:289–293CrossRefPubMed
26.
Zurück zum Zitat American Association of Electrodiagnostic M, Olney RK (1999) Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve Suppl 8:S225–S229 American Association of Electrodiagnostic M, Olney RK (1999) Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve Suppl 8:S225–S229
27.
Zurück zum Zitat Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ (1993) Severe axonal degeneration in acute Guillain–Barré syndrome: evidence of two different mechanisms? J Neurol Sci 116:185–192CrossRefPubMed Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ (1993) Severe axonal degeneration in acute Guillain–Barré syndrome: evidence of two different mechanisms? J Neurol Sci 116:185–192CrossRefPubMed
28.
Zurück zum Zitat Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK (1996) Pathology of the motor-sensory axonal Guillain–Barré syndrome. Ann Neurol 39:17–28CrossRefPubMed Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK (1996) Pathology of the motor-sensory axonal Guillain–Barré syndrome. Ann Neurol 39:17–28CrossRefPubMed
29.
Zurück zum Zitat Yuki N (2001) Infectious origins of, and molecular mimicry in, Guillain–Barré and Fisher syndromes. Lancet Infect Dis 1:29–37CrossRefPubMed Yuki N (2001) Infectious origins of, and molecular mimicry in, Guillain–Barré and Fisher syndromes. Lancet Infect Dis 1:29–37CrossRefPubMed
30.
Zurück zum Zitat Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N (2000) Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48:624–631CrossRefPubMed Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N (2000) Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48:624–631CrossRefPubMed
31.
Zurück zum Zitat Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (1993) A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178:1771–1775CrossRefPubMed Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (1993) A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178:1771–1775CrossRefPubMed
32.
Zurück zum Zitat Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA 101:11404–11409PubMedCentralCrossRefPubMed Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA 101:11404–11409PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Clouston PD, Kiers L, Zuniga G, Cros D (1994) Quantitative analysis of the compound muscle action potential in early acute inflammatory demyelinating polyneuropathy. Electroencephalogr Clin Neurophysiol 93:245–254CrossRefPubMed Clouston PD, Kiers L, Zuniga G, Cros D (1994) Quantitative analysis of the compound muscle action potential in early acute inflammatory demyelinating polyneuropathy. Electroencephalogr Clin Neurophysiol 93:245–254CrossRefPubMed
34.
Zurück zum Zitat Baba M, Matsunaga M (1984) Recovery from acute demyelinating conduction block in the presence of prolonged distal conduction delay due to peripheral nerve constriction. Electromyogr Clin Neurophysiol 24:611–617PubMed Baba M, Matsunaga M (1984) Recovery from acute demyelinating conduction block in the presence of prolonged distal conduction delay due to peripheral nerve constriction. Electromyogr Clin Neurophysiol 24:611–617PubMed
35.
Zurück zum Zitat Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, Hirata K, Baba H, Yuki N (2007) Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27:3956–3967CrossRefPubMed Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, Hirata K, Baba H, Yuki N (2007) Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27:3956–3967CrossRefPubMed
36.
Zurück zum Zitat Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK (1996) Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain–Barré syndrome. J Neurocytol 25:33–51CrossRefPubMed Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK (1996) Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain–Barré syndrome. J Neurocytol 25:33–51CrossRefPubMed
37.
Zurück zum Zitat Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, Rasband MN (2012) Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233:534–542PubMedCentralCrossRefPubMed Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, Rasband MN (2012) Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233:534–542PubMedCentralCrossRefPubMed
38.
Zurück zum Zitat Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, Arita M, Motoyoshi K, Kusunoki S (2008) GM1/GalNAc-GD1a complex: a target for pure motor Guillain–Barré syndrome. Neurology 71:1683–1690CrossRefPubMed Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, Arita M, Motoyoshi K, Kusunoki S (2008) GM1/GalNAc-GD1a complex: a target for pure motor Guillain–Barré syndrome. Neurology 71:1683–1690CrossRefPubMed
39.
Zurück zum Zitat Kusunoki S, Kaida K (2011) Antibodies against ganglioside complexes in Guillain–Barré syndrome and related disorders. J Neurochem 116:828–832CrossRefPubMed Kusunoki S, Kaida K (2011) Antibodies against ganglioside complexes in Guillain–Barré syndrome and related disorders. J Neurochem 116:828–832CrossRefPubMed
40.
Zurück zum Zitat Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S (2003) Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes. Neurology 61:471–474CrossRefPubMed Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S (2003) Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes. Neurology 61:471–474CrossRefPubMed
41.
Zurück zum Zitat van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC (2007) A clinical prognostic scoring system for Guillain–Barré syndrome. Lancet Neurol 6:589–594CrossRefPubMed van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC (2007) A clinical prognostic scoring system for Guillain–Barré syndrome. Lancet Neurol 6:589–594CrossRefPubMed
42.
Zurück zum Zitat Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC (2011) Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 76:968–975PubMedCentralCrossRefPubMed Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC (2011) Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 76:968–975PubMedCentralCrossRefPubMed
Metadaten
Titel
An electrophysiological classification associated with Guillain–Barré syndrome outcomes
verfasst von
Takafumi Hosokawa
Hideto Nakajima
Kiichi Unoda
Kazushi Yamane
Yoshimitsu Doi
Shimon Ishida
Fumiharu Kimura
Toshiaki Hanafusa
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 10/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7452-2

Weitere Artikel der Ausgabe 10/2014

Journal of Neurology 10/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.